Inflammation During ECMO Therapy and ECMO Weaning
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- Procedure: Ventilator weaning firstProcedure: ECMO weaning first
- Registration Number
- NCT05640635
- Lead Sponsor
- University Hospital Tuebingen
- Brief Summary
The goal of this interventional clinical trial is to compare patients who undergo ECMO therapy for treatment of acute respiratory distress syndrome (ARDS) and a randomized into one of two possible weaning strategy groups.
Group 1: Weaning from ventilator occurs before ECMO weaning.
Group 2: Weaning from ECMO occurs before weaning from ventilator.
This study investigates which one of these strategies is more indulgent for the lung, and leads to less inflammation and therefore less potential side effects and an overall more favourable clinical course.
As a primary criterion, measure of IL-6 in blood samples will beused. As secondary criterions, SOFA score at various time points, ventilation pressures, lung injury score (LIS), length of stay in the intensive care unit, and ventilator-associated pneumonia as well as levels of inflammatory cells and cytokines in both blood samples and bronchoalveolar lavage at different time points will be determined.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
- Acute respiratory distress syndrome (ARDS) according to the Berlin Definition (PaO2/FiO2 < 100) and treatment with veno-venous ECMO (vvECMO)
- Hemodynamic stability
- Lung compliance did not change/improved during the last 24 hours
- Tidal volume did not change/improved during the last 24 hours with a PEEP of 10 cmH20 or above
- Consent of the patient or their legal representative
- Age < 18 years
- Artificial ventilation for more than 7 days prior
- Patient, legal representative or doctors decided against an unrestricted intensive care treatment
- Positive pregnancy test at time of screening
- Cardiac failure requiring veno-arterial ECMO therapy
- Chronic respiratory insufficiency requiring long-term oxygen treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ventilator weaning first Ventilator weaning first - ECMO weaning first ECMO weaning first -
- Primary Outcome Measures
Name Time Method IL-6 concentration (blood samples) For the duration of the ICU stay, or a maximum of 60 days. Daily control of above mentioned parameter.
- Secondary Outcome Measures
Name Time Method Cytokines and inflammatory cells in bronchoalveolar lavage (IL-1beta, Il-10 and TNF-alpha) For the duration of the ICU stay, or a maximum of 60 days. Collection of bronchoalveolar lavage samples at various times points for further analysis.
Ventilation pressures For the duration of the artificial ventilation, or a maximum of 60 days. Pressures applied to the lung during artificial ventilation
Cytokines and inflammatory cells in blood samples (IL-1beta, Il-10 and TNF-alpha) For the duration of the ICU stay, or a maximum of 60 days. Collection of blood samples at various times points for further analysis.
SOFA-Score For the duration of the ICU stay, or a maximum of 60 days at indicated time points as described above.. Sequential organ failure assessement score evaluated at days 1-14, 28, and 60.
Murray Lung Injury Score (LIS) For the duration of the ICU stay, or a maximum of 60 days. Assessement of severity of lung damage by the established Lung Injury Score by Murray (Min Value is 0, healthy and Max Value is 20, severly diseased)
Length of stay in the intensive care unit For the duration of the ICU stay, or a maximum of 60 days. Length of stay in the intensive care unit.
Ventilator-associated pneumonia For the duration of the ICU stay, or a maximum of 60 days. Occurence/incidence of ventilator-associated pneumonia.
Trial Locations
- Locations (1)
University Hospital Tuebingen
🇩🇪Tuebingen, Baden-Wuerttemberg, Germany